You are missing the big picture.
IVXX is priced competitively compared to similar products in the market and the only way to offer a cheaper product is by using techniques that don't consider the patient.
(People with weakened immune systems should not be ingesting butane residue, for example)
IVXX is, for the moment, catering to more informed and health conscientious patients. (IVXX sells the same products without the fancy packaging btw) As people become more educated on their medicine (and what's in their medicine) they will gravitate away from the "more economical" choices.
Insurance companies will eventually cover the costs of medication as well and in order to keep their customers healthy they won't cover cheap residue pesticide etc laced products that cause more harm than good.
TRTC has always been thinking 3,4,5 steps ahead of the market.. The way IVXX is doing business is no different.
News 
Market Data 
Discover 
AI
